

Table 1: Comparison of plasmin- α 2-plasmin inhibitor, thrombin-antithrombin complex, tissue-type plasminogen activator-inhibitor complex, and thrombomodulin levels between a study group of 58 malignant tumor patients with venous thromboembolism (VTE) and a control group of 60 malignant tumor patients without VTE hospitalized at the same time.

Index	Control Group	Observation Group	z value	p-value
Age (year)	64 (56.25, 67.00)	65 (57.75, 68.00)	-1.333	0.182
Male/Female	36/24	33/25	-0.186	0.852
TAT (μ g/L)	3.60 (2.18, 6.28)	6.20 (2.8, 8.20)	-2.567	0.010*
PIC (mg/L)	0.51 (0.41, 0.64)	0.99 (0.65, 1.47)	-6.655	0.001*
tPAI-C (μ g/L)	7.40 (5.23, 11.65)	10.00 (6.43, 16.90)	-2.921	0.003*
TM (kU/L)	8.15 (6.43, 9.58)	8.00 (6.38, 10.53)	-0.701	0.483

Values are reported as the median, and first and third quartile in brackets or number. TAT: thrombin-antithrombin complex, PIC: plasmin- α 2-plasmin inhibitor complex, tPAI-C: tissue plasminogen activator-inhibitor complex, TM: thrombomodulin, *: statistically significant.